Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03301857 · ClinicalTrials.gov registry record · Phase 4
Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004
A Phase 4 study of Giant Cell Tumor of Bone, sponsored by Amgen.
- Completed
- Registry status
- Phase 4
- Development phase
- 85
- Enrollment target
- 14
- Study locations
NCT03301857 is a Phase 4 study of Giant Cell Tumor of Bone that has completed, run by Amgen. The registered enrollment target is 85 participants, below the 317-participant average among 3 other Giant Cell Tumor of Bone trials with a reported enrollment target (73% lower). The trial reports 14 study locations across 8 states.
The verdict
NCT03301857, a Phase 4 study of Giant Cell Tumor of Bone, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 85 participants
- Enrollment target
- 14
- Study locations
Study Summary
Study 20140114 will continue to follow participants with GCTB who were treated in Study 20062004 and remained on the study at the completion of Study 20062004 for an additional 5 years on long-term safety follow up.
Conditions Studied
Interventions
- DRUG Denosumab
Study Locations (14)
Other
- Centre Leon Berard - Lyon
- Institut Gustave Roussy - Villejuif
- Istituti Ortopedici Rizzoli - Bologna
- Instytut Matki i Dziecka - Warsaw
- Narodowy Instytut Onkologii im Marii Sklodowskiej-Curie â€" Panstwowy Instytut Badawczy - Warsaw
- Skane Universitetssjukhus - Lund
- Royal Orthopaedic Hospital - Birmingham
California
- Sarcoma Oncology Research Center LLC - Santa Monica
District of Columbia
- Washington Cancer Institute at MedStar Washington Hospital - Washington D.C.
Minnesota
- University of Minnesota Medical Center Fairview - Minneapolis
New York
- Mount Sinai Beth Israel Downtown - New York
Pennsylvania
- Abramson Cancer Center at Pennsylvania Hospital - Philadelphia
New South Wales
- Royal Prince Alfred Hospital - Camperdown
Balearic Islands
- Hospital Universitari Son Espases - Palma de Mallorca
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2017-11-13 |
| Est. Completion | 2023-07-27 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03301857
The ClinicalTrials.gov registry entry for NCT03301857 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 317-participant average among 3 other Giant Cell Tumor of Bone trials with a reported enrollment target (73% lower). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Giant Cell Tumor of Bone appearing as the primary indexed condition, and to 1 intervention - of which Denosumab is the first listed.
NCT03301857 reports 14 study locations spanning 8 distinct geographic areas - top geographies include Other, California, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT03301857 about?
NCT03301857 is a clinical study titled "Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004". Study 20140114 will continue to follow participants with GCTB who were treated in Study 20062004 and remained on the study at the completion of Study 20062004 for an additional 5 years on long-term safety follow up.
What is the current status of trial NCT03301857?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 85 participants. The study started on 2017-11-13. Estimated completion is 2023-07-27.
What conditions does trial NCT03301857 study?
This clinical trial studies the following conditions: Giant Cell Tumor of Bone.
What interventions are being tested in trial NCT03301857?
The interventions under investigation include: Denosumab (DRUG).
Who is sponsoring clinical trial NCT03301857?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03301857 being conducted?
This trial has 14 study locations across California, District of Columbia, Minnesota, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Giant Cell Tumor of Bone
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone
RECRUITING · Phase 3
-
PROMIS and Mobility Evaluation in Sarcoma Patients
RECRUITING
-
LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.